hOGG1 rs1052133 Polymorphism and Prostate Cancer Risk: A Chinese Case-Control Study and Meta-Analysis

31 October 2022: Clinical Research

Hanjiang Xu ^123BCDEF , Meng Zhang ^123BCDEF , Zongyao Hao ^123AC , Chaozhao Liang ^123A*

DOI: 10.12659/MSM.938012

Med Sci Monit 2022; 28:e938012

Table 4 Major features of eligible case-control studies recruited in the updated meta-analysis.

Author (ref.)	Date	Country	Race	Method	Case			Control			HWE
Author (ref.)	Date	Country	Race	Method	CC	CG	GG	CC	CG	GG	HWE
Xu et al	2002	USA	Mix	PCR	182	106	10	96	63	15	Y
Chen et al	2003	USA	Caucasian	RT-PCR	49	29	6	185	63	3	Y
Nam et al	2005	Canada	Mix	MS	593	350	53	617	386	89	N
Nock et al	2006	USA	Mix	PCR	280	135	24	305	142	31	N
Zhang et al	2010	USA	Mix	MS	126	61	4	118	71	7	Y
Lavender et al	2010	USA	African	TaqMan-PCR	132	58	4	452	173	21	Y
Dhillon et al	2011	Australia	Caucasian	PCR	38	57	21	69	50	12	Y
Mittal et al	2012	India	Asian	PCR	98	83	14	136	100	14	Y
Yun et al	2012	Korea	Asian	PCR	54	119	93	68	131	67	Y
Zhou et al	2013	China	Asian	PCR-RFLP	22	52	26	29	57	14	Y
Gong et al	2022	USA	Mix	PCR	354	227	33	423	229	37	Y
Xu et al	2022	China	Asian	Mass ARRAY	20	85	55	40	109	94	Y
Mix – from more than two races; HWE – Hardy-Weinberg equilibrium (Y means study consistent to HWE, and N means study did not consistent to HWE); PCR – Polymerase Chain RT-PCR – real-time PCR; MS – mass spectrometry; PCR-RFLP – PCR-restriction fragment length polymorphism.